Funding	VBG	O
for	IN	O
phage	NN	O
therapy	NN	O
research	NN	O
and	CC	O
clinical	JJ	O
trials	NNS	O
is	VBZ	O
generally	RB	O
insufficient	JJ	O
and	CC	O
difficult	JJ	O
to	TO	O
obtain	VB	O
,	,	O
since	IN	O
it	PRP	O
is	VBZ	O
a	DT	O
lengthy	JJ	O
and	CC	O
complex	JJ	O
process	NN	O
to	IN	O
patent	NN	O
bacteriophage	NN	O
products	NNS	O
.	.	O
Scientists	NNS	B
comment	NN	O
that	IN	O
'	``	O
the	DT	O
biggest	JJS	O
hurdle	NN	O
is	VBZ	O
regulatory	JJ	O
'	''	O
,	,	O
whereas	IN	O
an	DT	O
official	JJ	O
view	NN	O
is	VBZ	O
that	IN	O
individual	JJ	O
phages	NNS	O
would	MD	O
need	VB	O
proof	NN	O
individually	RB	O
because	IN	O
it	PRP	O
would	MD	O
be	VB	O
too	RB	O
complicated	JJ	O
to	TO	O
do	VB	O
as	IN	O
a	DT	O
combination	NN	O
,	,	O
with	IN	O
many	JJ	O
variables	NNS	O
.	.	O
Due	IN	O
to	IN	O
the	DT	O
specificity	NN	O
of	IN	O
phages	NNS	O
,	,	O
phage	NN	O
therapy	NN	O
would	MD	O
be	VB	O
most	RBS	O
effective	JJ	O
with	IN	O
a	DT	O
cocktail	NN	O
injection	NN	O
,	,	O
which	WDT	O
are	VBP	O
generally	RB	O
rejected	VBN	O
by	IN	O
the	DT	O
U.S.	NNP	O
Food	NNP	O
and	CC	O
Drug	NNP	O
Administration	NNP	O
(	-LRB-	O
FDA	NNP	O
)	-RRB-	O
.	.	O
Public	JJ	O
awareness	NN	O
and	CC	O
education	NN	O
about	IN	O
phage	NN	O
therapy	NN	O
are	VBP	O
generally	RB	O
limited	VBN	O
to	IN	O
scientific	JJ	O
or	CC	O
independent	JJ	O
research	NN	O
rather	RB	O
than	IN	O
mainstream	JJ	O
media	NNS	O
.	.	O
